**CASE STUDY**

**Diffuse alveolar damage in a patient treated with gemcitabine**


*Divisione di Broncopneumologia, Ospedale “E. Morelli”, Sondalo, Italy. **Servizio di Anatomia Patologica, Casa di cura S. Anna, Brescia, Italy.

Correspondence: A. Marruchella, Divisione di Broncopneumologia, Ospedale “E. Morelli”, 23039 Sondalo, Italy, Fax: 39 342 802146

Keywords: Acute interstitial pneumonia, antineoplastic agents, chemotherapy, diffuse alveolar damage, gemcitabine

Received: June 17 1997
Accepted after revision October 25 1997

Diffuse alveolar damage (DAD) is a descriptive term for the pathological findings following acute lung injury of several causes [1]. Many causes have been related to DAD: infectious agents, inhalants, connective tissue disease, drugs, shock, sepsis and radiation [1]. In the acute phase, there is oedema, epithelial necrosis and fibrinous exudate in alveolar spaces, with hyaline membrane formation. As the process organizes (organizing DAD), alveolar walls are lined by proliferating type II cells, there is a fibroblastic proliferation in the interstitium and airspaces, while hyaline membranes may be completely reabsorbed [1].

Acute interstitial pneumonia (AIP) is the pathological correlate of Hamman-Rich syndrome [1–3] and exhibits the changes described as organizing DAD.

We describe a case of DAD that occurred in a patient treated with gemcitabine, a novel chemotherapeutic agent that is structurally related to cytosine arabinoside, which is active against non-small cell lung cancer (NSCLC) [4, 5].

**Case report**

A 68 yr old man had undergone a left pneumonectomy for squamous cell lung cancer (tumour, node, metastasis (TNM) classification pT2N1M0, stage II) in June 1994. No other antineoplastic therapies had been administered. Because of hepatic metastases in July 1996, chemotherapy with gemcitabine was started (1,250 mg·m⁻², as a 30 min infusion once weekly for 3 weeks followed by a week of rest) [3]. Concomitant therapy included 12.5 mg of prednisone daily.

Six days after the sixth dose of gemcitabine (September 1996), the patient was admitted to hospital, because of mild fever, malaise, nonproductive cough and progressive dyspnoea. At physical examination there was cyanosis, and crackles were audible over the right lung field. Respiratory frequency was 24 breaths·min⁻¹; cardiac frequency 110 beats·min⁻¹; arterial blood pressure 120/80 mmHg. No clinical conditions known to be risk factors for acute respiratory distress syndrome (ARDS) were present [6]. Chest radiography showed left pneumonectomy and a right basilar shadow (fig. 1). Arterial blood gases revealed moderate hypoxaemia (arterial oxygen tension (\(P_{a,O_2}\)) = 7.0 kPa (53 mmHg)) corrected with \(P_{a,O_2}\) = 9.2 kPa (69 mmHg), and respiratory alkalosis (arterial carbon dioxide tension (\(P_{a,CO_2}\)) = 2.9 kPa (22 mmHg); pH=7.55). Laboratory tests did not show relevant abnormalities: white blood...
cell count (WBC) 5,610 cells·mm\(^{-3}\) with normal differential cell count, haemoglobin (Hb) 12.4 g·dL\(^{-1}\), platelets (PLT) 104,000/platelets·mm\(^{-3}\), glucose 135 mg·dL\(^{-1}\). Lactate dehydrogenase, transaminases, urea, Na\(^+\), K\(^+\) and Cl\(^-\) were in the normal range. Blood cultures were negative for aerobic and anaerobic bacteria. Serology for Mycoplasma, Legionella and respiratory viruses was negative. Broad-spectrum antibiotics (ceftazidime 2 g t.i.d. i.v. and gentamicin 80 mg b.i.d. i.v.) were started, without clinical benefit. Hypoxaemia became refractory to oxygen therapy (\(P_{a, O_2}/\text{inspiratory oxygen fraction (F}_{I, O_2}\) = 103) fulfilling the criteria for ARDS \[7\], and nasal continuous positive airway pressure (CPAP) (5 cmH\(_2\)O) was required to achieve an arterial oxygen saturation (\(S_{a, O_2}\)) >90%. Chest radiography showed extension of the basilar opacity, involving the whole right lung (fig. 2). Therapy with trimethoprim-sulphamethoxazole (5 mg·kg\(^{-1}\) trimethoprim and 25 mg·kg\(^{-1}\) sulphamethoxazole q.i.d. i.v.) and methylprednisolone (2 g daily i.v.) was instituted. There was a clinical worsening, and the patient died 4 days after admission. He had declined mechanical ventilation.

Pathological findings

At autopsy the right lung appeared heavy and stiff, without macroscopic focal lesions. Light microscopic examination revealed a pattern of DAD, with necrotic lesions of alveolar walls and hyaline membranes (fig. 3); occasional myxomatous organizing buds were seen in alveolar spaces. Rare silicotic nodules were present. Lesion attributable to viral infection or other specific aetiologies were absent. Tissue staining for Mycobacteria, fungi and Pneumocystis carinii were negative, as were tissue cultures for bacteria, Mycobacteria and fungi.

Discussion

Many drugs have been related to lung injury with a DAD pattern \[1, 8, 9\]. The major group consists of antineoplastic agents \[10\]. The clinical features of lung toxicity are not specific (dyspnoea, cough, fever, pulmonary infiltrates) and the differential diagnosis includes infection, relapse of the underlying disease, pulmonary oedema and changes due to oxygen or radiation \[1, 8\]. The pathological findings of drug-related DAD are also quite nonspecific \[1\] and the diagnosis is one of exclusion. In our case the clinical history and the exclusion of other identifiable inciting factors suggest the antineoplastic drug as the cause of lung injury. The clinical onset and the pathological pattern are consistent with a dose-related toxicity.

Gemcitabine is an analogue of deoxycytidine recently introduced in clinical use \[4, 5\]. Unlike cytosine arabinoside (Ara-C), a structurally similar analogue, gemcitabine has significant activity against solid tumours. In all of the NSCLC trials, toxicity was modest, thrombocytopenia and neutropenia being the most frequent toxic effects \[5\]. Transient dyspnoea, the pathogenesis of which is unknown, has been reported in about 10% of patients soon after the infusion \[5\]. In a recent update, gemcitabine was not included among "drugs that may injure the respiratory system" \[9\]. To our knowledge, seven cases of drug-related pulmonary toxicity termed "lung oedema", have been suspected (Eli Lilly and Co., Clinical Investigator's Brochure, 1995, with permission), but there was no pathological confirmation. Recently, pulmonary toxicity resulting from treatment with gemcitabine has been described in three patients, two of whom died \[13\]. Postmortem examination revealed pathological findings consistent with ARDS. In the fatal cases, radiological signs of pulmonary toxicity appeared during cycle 6 and 2, respectively. In one patient, who recovered after withdrawal of gemcitabine (cycle 3) with corticosteroids, transbronchial lung biopsy showed nonspecific interstitial pneumonitis.

The similar analogue Ara-C has been associated with noncardiogenic pulmonary oedema \[8, 10, 12, 13\]. In the reported cases, symptoms occurred either while taking the drug, or up to 28 days after cessation of therapy. In a large series, acute respiratory failure developed in 13 of 103 (12%) patients treated with high-dose Ara-C for acute leukae-
mia. Nine of the patients died; autopsy was performed in seven, and revealed "oedema alone" in six cases and "diffuse alveolar damage" in one case [12].

We conclude that severe respiratory failure with a histological pattern of alveolar damage can develop during treatment with gemcitabine. This requires careful follow-up of patients treated with this drug.

References